Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2015-06-04 Board/Management Inform…
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically reports the resignation of a senior officer, John E. Sawyer, from his position as Senior Vice President. This corresponds to an announcement of changes in the company's senior management. The document is short (2250 characters) and focuses solely on management changes without financial data or other report content. Therefore, it fits the category of Board/Management Information (MANG).
2015-06-04 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a common stock purchase agreement and registration rights agreement with Aspire Capital. It details the terms of the financing arrangement, including purchase rights, pricing, and termination conditions. The document also includes references to exhibits such as the agreements and a press release. There are no financial statements or detailed financial performance data included, nor is this a full annual or quarterly report. The primary purpose is to update investors on a capital raising transaction. Therefore, this filing fits the category of a Capital/Financing Update (CAP).
2015-05-28 English
FORM 4
Director's Dealing
2015-05-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (an Intellectual Property License Agreement) between Atossa Genetics Inc. and Besins Healthcare Luxembourg SARL. There are no financial statements or detailed financial data presented, only a description of the agreement terms and conditions. The document is relatively short (4315 characters) and serves as an announcement of a significant corporate event rather than a full financial report or detailed management discussion. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2015-05-18 English
FORM 4
Director's Dealing
2015-05-14 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated May 11, 2015. It reports the submission of matters to a vote of security holders at the company's 2015 Annual Meeting of Stockholders, including election of directors and ratification of auditors. The document provides detailed voting results but does not contain financial statements or substantive financial data. The document length is 3521 characters, which is relatively short and primarily reports voting results. According to the filing definitions, official results from shareholder votes at any general meeting (AGM or EGM) fall under Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, this document is best classified as DVA.
2015-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.